Insilico Medicine and SK Biopharmaceuticals expanded their partnership with a large, heavily backloaded AI drug discovery deal focused on neuroimmune disorders. Coverage says the deal value could exceed $2.5 billion, reflecting both the scale of expectations for computational discovery and the continuing shift toward AI-enabled target finding. The collaboration is positioned around searching for drug candidates, with the parties combining Insilico’s AI discovery approach and SK Biopharmaceuticals’ development and commercialization capabilities. Backloaded structures typically signal milestone-driven economics tied to candidate progress, adding pressure for effective translation from computational leads into preclinical development and eventual clinical entry.